ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Sets Up U.S. Vaccine Center

by Ann M. Thayer
April 13, 2015 | APPEARED IN VOLUME 93, ISSUE 15

GlaxoSmithKline will create a new global center for vaccines R&D in Rockville, Md. The firm will consolidate vaccines R&D under way in Cambridge, Mass., and Philadelphia at the Maryland site. Starting up as early as September, the new site will house about 1,000 people by 2016, including about 400 already working there in manufacturing. GSK employs about 150 people at both the Cambridge and Philadelphia sites. Besides the Rockville site, which GSK acquired in 2012, the firm has vaccine R&D centers in Rixensart, Belgium, and Siena, Italy. GSK added the Siena site when it acquired Novartis’s vaccines business last month.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment